1. Pink Sheet

AstraZeneca/Avillion Asthma Combo Draws Split Decision At FDA Panel; Data Was ‘All Over The Place’

 
• By Sue Sutter

In near unanimous votes, advisory committee rejects budesonide/albuterol sulfate fixed-dose combination for young children but favors approval for adults; the vote in adolescents was more divided, with some panelists believing extrapolation of adult efficacy data were appropriate for this population.

Beads
Several panelists on both sides of the vote in adolescents said they would give deference to FDA on this population in light of the agency’s past experience with extrapolating adult efficacy data. • Source: Shutterstock

A US Food and Drug Administration advisory committee overwhelmingly voted 8 November that adult efficacy data for Avillion LLP and AstraZeneca PLC’s novel budesonide/albuterol sulfate product could not be extrapolated to young children with asthma, but the panelists were more closely divided on the question of whether such data could support approval in adolescents.

After voting 16-1 that the data supported a favorable benefit-risk assessment for use of the fixed-dose combination of budesonide and albuterol sulfate (BDA) in asthma patients ≥18 years, the Pulmonary-Allergy Drugs Advisory Committee voted 9-8

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers